Repletion of Ergothioneine in Patients With Kidney Failure
Recruiting · NCT06487546 · Interventional (participants receive a specific treatment) · Lead sponsor: Stanford University
View the official record on ClinicalTrials.gov →Interventions studied
ErgothioneinePlacebo
What this trial is about
Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- kidney failure receiving hemodialysis or peritoneal dialysis
Exclusion criteria
- blood transfusion within 90 days
- taking supplements which contain ergothioneine
Where it is running
1 location listed across 1 US state.
- Veterans Affairs Palo Alto - Palo Alto, California, United States